Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


LH vs. CRL: Which Stock Is the Better Value Option?

2026-06-15
LH vs. CRL: Which Stock Is the Better Value Option?

CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?

2026-06-12
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Strong Performance Continues at DHR's Biotechnology Unit: What's Next?

2026-06-11
Danaher is seeing strong Biotechnology growth as bioprocessing demand rises, with equipment orders up more than 30% and core revenue gains expected in 2026.

2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges

2026-06-10
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

2026-06-08
Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threateni

Top S&P500 movers in Friday's pre-market session

2026-06-05
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.

Why Is Pediatrix Medical Group (MD) Down 1.7% Since Last Earnings Report?

2026-06-04
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

2026-06-03
Labcorp Holdings Inc. (LH) Jefferies Global Healthcare Conference 2026 June 3, 2026 12:15 PM EDTCompany ParticipantsJulia Wang - CFO & Executive...

Assessing Labcorp (LH) Valuation As Shares Cool And P/E Trails Healthcare Peers

2026-06-02
Labcorp Holdings stock snapshot Labcorp Holdings (LH) stock has been moving without a clear single catalyst, which leads many investors to focus on its fundamentals, including recent returns, revenue, earnings and its current valuation profile. See our latest analysis for Labcorp Holdings. At a share price of $256.87, Labcorp Holdings has seen its short term share price momentum cool, with the share price down over the past week and three months, while longer term total shareholder returns...

LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?

2026-06-01
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.